ANGO icon

AngioDynamics

10.66 USD
-0.23
2.11%
At close Jun 13, 4:00 PM EDT
After hours
10.50
-0.16
1.50%
1 day
-2.11%
5 days
-3.62%
1 month
13.40%
3 months
16.89%
6 months
18.44%
Year to date
18.71%
1 year
71.38%
5 years
2.01%
10 years
-35.63%
 

About: AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.

Employees: 748

0
Funds holding %
of 7,296 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

133% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 15

100% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 2 (+1) [Q1 2025]

14% more funds holding

Funds holding: 134 [Q4 2024] → 153 (+19) [Q1 2025]

9% more capital invested

Capital invested by funds: $303M [Q4 2024] → $330M (+$27.3M) [Q1 2025]

5.37% more ownership

Funds ownership: 81.41% [Q4 2024] → 86.79% (+5.37%) [Q1 2025]

22% less repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 58

31% less call options, than puts

Call options by funds: $351K | Put options by funds: $510K

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$16
50%
upside
Avg. target
$16
50%
upside
High target
$16
50%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Yi Chen
50%upside
$16
Buy
Maintained
7 Apr 2025

Financial journalist opinion

Based on 4 articles about ANGO published over the past 30 days

Negative
Zacks Investment Research
6 days ago
Zacks Industry Outlook Penumbra, Integer and AngioDynamics
Zacks names PEN, ITGR and ANGO as medical device stocks riding genAI advances, despite global and inflationary headwinds.
Zacks Industry Outlook Penumbra, Integer and AngioDynamics
Positive
Zacks Investment Research
1 week ago
3 Medical Instruments Stocks Winning Big With GenAI Amid Global Gloom
PEN, ITGR and ANGO from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and supply issues mar prospects.
3 Medical Instruments Stocks Winning Big With GenAI Amid Global Gloom
Positive
Zacks Investment Research
1 week ago
What Makes AngioDynamics (ANGO) a Strong Momentum Stock: Buy Now?
Does AngioDynamics (ANGO) have what it takes to be a top stock pick for momentum investors? Let's find out.
What Makes AngioDynamics (ANGO) a Strong Momentum Stock: Buy Now?
Negative
Zacks Investment Research
2 weeks ago
Are Medical Stocks Lagging AngioDynamics (ANGO) This Year?
Here is how AngioDynamics (ANGO) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year.
Are Medical Stocks Lagging AngioDynamics (ANGO) This Year?
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts See a 63.23% Upside in AngioDynamics (ANGO): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 63.2% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See a 63.23% Upside in AngioDynamics (ANGO): Can the Stock Really Move This High?
Positive
Zacks Investment Research
2 months ago
Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year?
Here is how AngioDynamics (ANGO) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year?
Positive
Zacks Investment Research
2 months ago
Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 68.28%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 68.3% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 68.28%: Read This Before Placing a Bet
Positive
Zacks Investment Research
2 months ago
AngioDynamics Stock Up on Q3 Earnings Beat, Gross Margin Expands
ANGO reports solid fiscal third-quarter earnings with continued strength in its Med Tech segment. The expansion of gross margin bodes well.
AngioDynamics Stock Up on Q3 Earnings Beat, Gross Margin Expands
Positive
Benzinga
2 months ago
Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance
AngioDynamics Inc. (NASDAQ: ANGO) on Wednesday reported a third-quarter 2025 adjusted EPS of 3 cents, compared to the consensus for a per-share loss of 13 cents.
Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance
Neutral
Seeking Alpha
2 months ago
AngioDynamics, Inc. (ANGO) Q3 2025 Earnings Call Transcript
AngioDynamics, Inc. (NASDAQ:ANGO ) Q3 2025 Earnings Conference Call April 2, 2025 8:00 AM ET Company Participants Jim Clemmer - President & CEO Stephen Trowbridge - EVP & CFO Conference Call Participants John Young - Canaccord Genuity Steven Lichtman - Oppenheimer Eduardo Martinez - H.C. Wainwright Operator Good morning, and welcome to the AngioDynamics Fiscal Year 2025 Third Quarter Earnings Call.
AngioDynamics, Inc. (ANGO) Q3 2025 Earnings Call Transcript
Charts implemented using Lightweight Charts™